Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia.

ABSTRACT:

Introduction

Survival benefit associated with intensive over low-intensity chemotherapy in older adults with acute myeloid leukemia (AML) is controversial. Geriatric assessment and genetic risk categories correlate with survival following intensive chemotherapy in older adults with AML and can guide treatment selection.

Materials and methods

In a single-center trial, we integrated both geriatric assessment, and genetic risk categories to personalize selection of intensive versus low-intensity chemotherapy in older adults ≥60 years with AML (NCT03226418). In the present report, we demonstrate feasibility of this approach.

Results

Broad eligibility criteria and co-management of patients with community oncologists allowed enrollment of 45% of all patients with AML treate

SUBMITTER: Bhatt VR 

PROVIDER: S-EPMC9482687 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature